Authors
Latest:
Novartis' Rapcabtagene Autoleucel Produces Durable Response in Relapsed/Refractory DLBCLRates of complete response to the novel CAR-T varied from 67% to 75% across the 4 dosage levels tested.
Latest:
Heather Lau, MD, MS, on Using Heparan Sulphate as a Biomarker in the Clinical Study of MPSIIIA Gene Therapy UX111The executive director of global clinical development at Ultragenyx Pharmaceutical discussed the statistical findings she presented at the 2024 WORLDSymposium.
Latest:
Tom Van Blarcom, PhD, on Bringing CAR-T Constructs From Oncology to B-Cell Driven Autoimmune DiseaseThe senior vice president and head of research at Kyverna Therapeutics discussed the company’s investigational CAR-T therapies, KYV-101 and KYV-201.
Latest:
DLBCL Second-Line Therapy RecommendationsExperts discussed their recommendations for second-line treatment options for patients with DLBCL.
Latest:
Brian Van Tine, MD, PhD, on Looking Ahead on Cell Therapy for SarcomasThe professor of medicine and pediatrics at Washington University in St. Louis discussed future challenges and exciting research in the sarcoma field.
Latest:
Developing Personalized Immunotherapies for Solid TumorsJessica Baker Flechtner, PhD, chief scientific officer, Genocea, discussed the company’s focus on solid tumors and manufacturing cell therapies.
Latest:
Ahmad Masri, MD, MS, on the Potential of Cell Therapy in Light Chain AmyloidosisFor World Amyloidosis Day, the cardiologist at the Center for Hypertrophic Cardiomyopathy at Oregon Health & Science University discussed how Nexcella’s NXC-201 could help address unmet needs.
Latest:
Developing MCO-010 for Retinal Degenerative DiseasesSamarendra Mohanty, PhD, cofounder and president, Nanoscope Therapeutics, discussed the company’s technological platforms and RESTORE trial data.
Latest:
Collaboration and Expertise Is Crucial for Cell and Gene Therapy Clinical Trial SuccessParexel cell and gene therapy director Izaskun Elorza, MD, shares key factors for industry to consider as this emerging field becomes more prominent.
Latest:
Supporting the Development of Cell and Gene TherapiesThe chief executive officer of FlowMetric discussed the company’s role in supporting the development of novel gene and cell therapies.
Latest:
Leaping the Next Hurdle in CAR T-Cell TherapiesPhil Cyr, Senior Vice President, Precision Value & Health, discussed challenges to tackle with CAR T-cell therapies.
Latest:
Wolfgang Miesbach, MD, PhD, on Future Research with EtranaDezThe professor and head of coagulation disorders and Comprehensive Care Centre, University Hospital of Frankfurt, Germany, discussed future integration of EtranaDez into hemophilia B treatment.
Latest:
Paulina Velasquez, MD, on Finding New Targets for Cell TherapyThe assistant member at St. Jude Children’s Research Hospital discussed the ASH 2022 basic and translational science session she moderated.
Latest:
Improving Practicality of Cell and Gene TherapiesJosh Ludwig, global director, commercial operations, ScaleReady, discussed making cell and gene therapy widely practical and viable for patients with cancer.
Latest:
Scott McClellan, MD, on Current Trends and Future Trajectories in Cell TherapyThe chief medical officer of Orca Bio discussed some trends he was excited about at ASH’s 2023 conference.
Latest:
Alan Beggs, PhD, on Challenges in Therapeutic Development for Rare DiseasesThe director of the Manton Center for Orphan Disease Research at Boston Children’s Hospital discussed takeaways from an MDA session on rare diseases.
Latest:
Brian Koffman, MDCM, on Keeping Pace in Chronic Lymphocytic Leukemia ResearchThe cofounder, executive vice president, and chief medical officer, CLL Society, discussed unmet needs that remain for people with CLL and how the society is working to advance research in the field.
Latest:
Alan Trounson, PhD, MSc, on New Frontiers in Allogeneic Cell TherapyThe chief executive officer of Cartherics discussed the company’s development of NK cell, T-cell, and macrophage cell therapies for various solid tumor indications.
Latest:
Lawrence R. Lustig, MD, on Evaluating Gene Therapy for the Treatment of Otoferlin-Related Hearing LossThe chair of the Department of Otolaryngology—Head and Neck Surgery at Columbia University College of Physicians discussed the phase 1/2 CHORD clinical trial evaluating DB-OTO.
Latest:
Stella Vnook, PharmD, on Improving Cell Therapy Delivery to Solid Tumors With Core Shell SpherificationThe chief executive officer of Likarda discussed the company’s CSS technology and how it may reduce off-tissue effects.
Latest:
Paul Harmatz, MD, on Harnessing Accelerated Approval for LSDs, Rare Disease Treatment AdvancementsThe pediatric gastroenterologist and professor in residence at University of California at San Francisco discussed challenges in investigating therapies for rare diseases.
Latest:
CAR T as Frontline Therapy for DLBC Lymphoma: Alex Herrera, MDThe hematologist/oncologist from City of Hope discussed the potential for CAR T-cell therapy in earlier lines of treatment for patients with diffuse large B-cell lymphoma.
Latest:
Roberto Giugliani, MD, PhD, on Advantages of Gene Therapy in MPS Type 2The professor of genetics at Federal University of Rio Grande do Sul discussed how RGX-121 has the potential to change the treatment landscape of MPSII.
Latest:
Liso-Cel Approval Expands CAR T-Cell Access in LBCLNilanjan Ghosh, MD, PhD, discussed the impact of liso-cel's approval.
Latest:
Risk Alleles in Age-Related Macular Degeneration: Steffen Schmitz-Valckenberg, MDThe ophthalmologist from John A. Moran Eye Center discussed the close association between disease progression and uncovered risk alleles.
Latest:
Frederick Locke, MD, and Michael Jain, MD, PhD, on Why Some Patients With Lymphoma Do Not Respond to Cellular ImmunotherapyCancerNetwork® was joined by 2 clinicians from Moffitt Cancer Center to discuss why some patients do not respond to CAR T-cell therapy, despite the significant promise of the treatment modality.
Latest:
Marco Davila, MD, PhD, on Investigating Mechanisms of CAR T Resistance in B-cell MalignanciesThe vice chair for cellular therapies at Roswell Park Comprehensive Cancer Center discussed new research from the center presented at the 2023 Tandem Meetings.
Latest:
CAR T Therapy Yields Remission in Systemic Lupus ErythematosusFive patients with lupus treated with anti-CD19 CAR T-cell therapy are now in remission.
